It is well accepted that acetylcholine is involved in memory and learning processes and that loss of memory is characteristic of Alzheimer's disease (AD). Several muscarinic agonists have been shown to be clinically effective in the treatment of AD. However, their use has been limited due to adverse side effects. As a result, more selective M1 agonists are expected to be the next generation of agents for the treatment of AD. One pharmacological approach to evaluate possible cognitive effects of compounds includes their ability to reverse scopolamine-induced amnesia. In the current study the succinamide and succinimide of p-aminophenol, two newly synthesized compounds that were previously designed to be acetylcholine analogues, were evaluated in a Pavlovian/Instrumental autoshaped memory task. Simultaneously, docking studies on the M1 receptor were done. The scopolamine-induced amnesia was reversed by the amide but not the imide. These findings are in line with results derived from the docking simulations, and suggest that at least the succinamide of p-aminophenol could represent a novel candidate for the treatment of AD.
INTRODUCTION
Replacement of the lost cholinergic function is an attractive proposition for the treatment of Alzheimer's disease (AD), but the cognitive enhancement caused by cholinomimetics developed to date has been compromised by their low bioavailability and strong side effects.
The distribution of muscarinic receptor (mAChR) subtypes in the central nervous system has been investigated mainly by pharmacological studies with relatively good subtype-selective agents well as by molecular, immunohistochemical, immunoprecipitational studies that measure the expression of mRNA levels and receptor protein, and specific methylscopolamine binding in various brain areas of wild-type and mAChR subtypes of knockout mice. According to these reports, the M1 mAChR is abundantly expressed in all forebrain areas including the cerebral cortex and hippocampus, where this subtype consists of 40-50% of the total mAChR [1] . It is known that the M1 subtype in the cerebral cortex and hippocampus may play an important role in higher cognitive processes such as learning and memory [2] . These findings led to the hypothesis that agonists demonstrating selectivity for the M1 subtype could have therapeutic utility for AD by enhancing cognition. Furthermore, M1 agonists, but not cholinesterase inhibitors (CHE-Is), increase the release of soluble amyloid precursor proteins and decrease that of -amiloid proteins [3, 4] . Thus, selective M1-receptor agonists are expected to be potential cognitive enhancers with much lower incidence of adverse effects than CHE-Is [3, 4] . Unfortunately, because of the high conserva-*Address correspondence to this author at the Escuela Superior de Medicina, Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación y Departamento de Bioquímica, Plan de San Luis y Díaz Mirón, México, D.F., 11340 México; E-mail: judith.espinosa@terra.com.mx tion of the agonist binding site across the five subtypes [5] , it has been difficult to synthesize compounds that demonstrate M1 subtype selectivity [6] .
It is well known that muscarinic receptors contain primary sites (orthosteric sites), where acetylcholine (ACh) agonists and competitive antagonists bind. These receptors have one or more allosteric sites that mediate the effects of various agents on the binding of ligands at the orthosteric site [7] . The binding of the allosteric ligand to the allosteric site alters the affinity with which the muscarinic ligand binds to the primary binding site at the receptor [8] . The cooperative effect of an allosteric agent depends on the particular primary (muscarinic) ligand with which it interacts and may be positive, negative or neutral. If neutral, the allosteric agent binds to the receptor without affecting the affinity of the primary ligand. [9] Allosteric agents that increase the affinity of the endogenous ligand, known as allosteric enhancers, may have a number of therapeutic advantages compared with agonists that act directly. Such advantages include the possibility of an absolute receptor subtype selectivity (because the allosteric site is the least well conserved region of muscarinic receptors) [7, 8] , independently of the dose or affinity of the allosteric agent. Even, this latter can show positive cooperativity with the endogenous ligand at only one receptor subtype, but neutral cooperativity with all the others [9, 10] . Thus, it is possible to design compounds that are able to enhance cognition without undesirable side effects.
Previously, two succinic acid derivatives which could be ACh analogues were designed and synthesized [11, 12] Fig.  (1) . Taking this information into account and considering that M1 mAChR are closely related with higher cognitive function, the capacity of these succinic acid derivatives to reverse the scopolamine-induced amnesia in a Pavlovian/ Instrumental autoshaped (P/I-A) memory test was evaluated. Several docking simulations based on Hulme's Homology model, confirmed that these act on M1 mAChR.
MATERIAL AND METHODS

Animals
Male Wistar rats (200-250 g) were collectively housed in a light-controlled room under a 12:12 h light:dark inverted cycle. Water and food were available ad libitum. On the day before the behavioral test, the food was withdrawn. All procedures were conducted following the Mexican Official Norm for Animal Care and Handling (NOM-062-ZOO-1999).
Drugs
Galanthamine (4.5 mg/kg, GAL) and scopolamine (2.0 mg/kg, SCO) were purchased from Sigma Chem. USA. Succinic acid derivatives: p-hydroxyl-phenylsuccinamide (1.25, 2.5, 5.0 and 10 mg/kg, (1)) and p-acetyl-phenylsuccinimide (10 mg/kg, (2)) were synthesized in our laboratory [11] . GAL and SCO were dissolved in physiological saline, while succinic acid derivatives were emulsified in sesame oil. All compounds were intraperitoneally administered at 1 ml/kg b.w.
Autoshaping Learning Task
As occurs in Pavlovian autoshaping, conditioned stimulus (CS) and unconditioned stimulus (US) are independent of the behavior of the animal because autoshaped behavior is minimally affected by instrumental responses. Importantly, within the continued progress of behavioral task deveploment, a P/I-A task combines both Pavlovian and instrumental conditioning. The latter offers the opportunity to study hipoccampus-mediated declarative memory and striatum-mediated Response-Stimulus "habit formation". Furthermore, P/I-A task is almost completely automated, thus reducing human intervention, and is sensitive to small increases or decreases in various behavioral parameters, including sign tracking and goal tracking. The latter parameter is quite important, as it allows for the study of bidirectional expression of an improved or impaired memory formation. In addition, as in other associative learning tasks, autoshaped responses are rapidly observed when trials are spaced in time, and its acquisition speed is relatively constant when the CS/US intertrial ratio interval is constant [13] .
A Skinner box (WMPC 1999; Med Associates Inc. USA) was used for training. Animals were organized into groups, each of which was given saline, SCO, GAL, (1) (10 mg/kg) or (2) (10 mg/kg). Then, a mixture of SCO with GAL and several doses of each succinic acid derivative were assayed in independent groups. Succinic acid derivatives were administered 45 minutes previous to, while SCO was administered at the end of the first session.
The autoshaping task was as follows: a hungry animal was placed in a Skinner box to find food pellets (US) and was then given a Pavlovian sequential pairing (stimulusstimulus[S-S]) of light and lever (CS), followed by food (US). After a number of such presentations, the animal approached the CS and presented a conditioned response (CR), such as contact or lever-press. The increase or decrease of the CR was considered an enhancement or impairment of learning, respectively. Each animal was placed in the experimental chamber for a habituation period of 10-15 min with access to 20 food pellets (45 mg each). The threeautoshaping training sessions, one every 24 h, consisted of 20 trials for the first and second sessions, and 10 trials for the third. Final memory results corresponded to the latter [13] .
Molecular Docking on the M1 Muscarinic Receptor
The docking simulations were carried out with the Autodock program. The homology model of the M1 mAChR reported by Hulme and co-workers was used [14] . Polar hydrogens were added to the protein, followed by a short energy minimization using the program NAMD and the AM-BER force field. Kollman charges and solvatation parameters were assigned to the atoms of the protein. [15, 16] ACh, SCO, (1) and (2) were constructed and optimized employing the Hyperchem Program. Each molecule was equipped with Gasteiger charges and the torsion angles were assigned using AUTOTORS. The grid maps representing the protein in the current docking experiments were calculated by using the AUTOGRID utility, included in AUTODOCK. Dimensions of the maps were 100 100 100 points with a spacing of 0.8 Å, thus being big enough to cover the entire surface of the protein. [15, 16] For the docking simulations, the hybrid Lamarckian Genetic Algorithm/local search was employed. An initial population of 300 individuals, 50,000,000 energy evaluations, 50,000 generations and 100 independent runs were set for performing the docking experiments. The rest of the parameters remained unmodified. [15, 16] 
Statistical Analysis
Data were analyzed with one way ANOVA and Tukey's t test for multiple comparisons. A p value of less than 0.05 was considered significant. Fig. (2) shows that the administration of SCO resulted in a pronounced reduction in CRs compared with vehicle- Fig. (3) shows that GAL and several doses of (1) reversed the scopolamine-induced amnesia, F (6, 48) = 15.38, p < 0.001 (right panel). In the same panel, only 2.5 mg/kg of (1) showed a difference compared with the control. Docking studies showed that ACh, SCO and (2) docked in the aromatic cage located close to the extracellular domain of the receptor ( G b -4.7, -10.48, and -7.5 kcal/mol, respectively), as previously reported [14] . The aromatic cage is located among the transmembrane domains 3, 5, 6 and 7. (1) Fig. (2) . Effect of all tested drugs on the performance of rats in the autoshaping learning task. Each bar represents the mean + SEM of eight animals. SCO (scopolamine), GAL (galanthamine). p < 0.001 vs. all others. Fig. (3) . Reversal of scopolamine-induced amnesia by (1) . Each bar represents the mean + SEM of eight animals. VEH (vehicle), SCO (scopolamine), GAL (galanthamine). *p<0.001 vs. all others; #p<0.05, SCO + (1) 2.5 mg/kg vs. VEH. preferentially docked in two different sites (Fig. (5) ): the ligand binding site ( G b -6.95 kcal/mol) and another binding site near the intracellular loop 3 and the transmembrane domain 6 between the residues N93, T225, E226, K233, A234, N60, N61, K230, V229, S227, T58, N293, A295 ( G b -7.81 kcal/mol; based on Hulme's Homology model). 
RESULTS
DISCUSSION
The mAChRs are single subunit proteins with seven transmembrane-spanning regions and cytoplasmic domains between the transmembrane segments five and six. Currently, site-directed mutagenesis studies of rat mAChRs suggest that the ACh binding site consists of a series of hydrophobic amino acids located in the "upper" half of transmembrane domains III, V, VI and VII. The regions near the transmembrane segments in the second and third internal loops and the N-terminal portion of the third intracellular loop are thought to be involved in the interaction with G proteins. The mAChRs are involved in the control of extrapyramidal locomotor activity and higher cognitive processes, such as learning and memory. The differential distribution of mAChRs subtypes in the brain suggests that the M1 subtype may be particularly important for cognitive processes, since this receptor is rich in forebrain areas such as neostriatum, amygdala, hippocampus, and cerebral cortex, where cholinergic synapses seem to mediate acquisition and storage of new information. [17] As it has been proposed that ACh is involved in memory and learning [17, 18] , one pharmacological approach to evaluate possible cognitive effects of compounds includes their ability to reverse the scopolamine-induced amnesia [19, 20, 21, 22] . Lesion studies that employed destruction of the basal forebrain have been used to induce cognitive impairments in animals [20] , and it has been found that cholinergic blockage results in acquisition impairment and retrograde amnesia in various animal species regarding different learning tasks [13, 19, 20, 21, 22, 23] . Nowadays, SCO is still used to evaluate the role of the cholinergic system in acquisition, consolidation, and retrieval memories. [13, 21, 22] .
Taking into account that P/I-A task requires an intact neuronal system in the hippocampus, septum, and cortex, as well as the participation of the cholinergic signaling transduction pathways in the integration of autoshaping cognitive tasks (acquisition-consolidation process) [24] , it was chosen to evaluate the effect of the succinic acid derivatives on scopolamine-induced amnesia. The SCO dose used was chosen based on previous reports showing effects on memory at doses ranging from 0.2-2.0 mg/kg [21, 22, 25, 26] . SCO did not produce motor effects (t = 0.926, p>0.3; data not show) and did not interfere with the task because it is administered at the end of the first session. The administration of SCO immediately after the first session resulted in a pronounced reduction in CRs compared with vehicle-injected animals, suggesting impairment of consolidation. Results indicate that (1), but not the (2) derivative, reversed the scopolamineinduced amnesia.
A possible explanation of the action of (1) could be given by the docking studies at M1 mAChR. Recent studies have shown the existence (from docking simulations) of three allosteric sites involved not only in the positive cooperativity with the orthosteric site, but also in the activation of a possible ACh-independent G-protein coupling to the receptor [16, 27] . The existence of an allosteric site located at the intracellular domain of the receptor could play an important role in "allowing" or "stopping" the energy flow along the transmembrane domains and thus could work as an "energy transduction breaker". It has been hipothetized that, in certain cases, the agonist-binding process could be replaced by allosteric activation. In this particular case, G protein-coupling could be agonist-binding independent, via the conformational rearrangement of the intracellular face of the receptor [16] .
The current study shows that (1) may bind at both the ligand-binding site and the intracellular allosteric site, which might display a complex allosteric mechanism. This process Fig. (4) . Reversal of scopolamine-induced amnesia by (2) . Each bar represents the mean + SEM of eight animals. VEH (vehicle), SCO (scopolamine), GAL (galanthamine). p< 0.001; SCO vs. VEH or SCO + GAL.
can be dependent on or independent of the agonist binding to the receptor [16, 27] . Thus, the effect of the (1) in the autoshaping learning task might be due to the dual interaction of the compound at the M1 mAChR. In contrast, (2) only behaves as an agonist. In this case, SCO (which displays a better binding free energy) would easily displace (2) and therefore would neutralize its agonistic action, a finding consistent with the results of the autoshaping learning task. Nevertheless, it is important to carry out more experiments to clarify this proposal.
The allosteric ligands of cell-surface receptors might be suitable for most systems where the orthosteric agonism is desired, especially in situations where the enhancement of the endogenous signal is the preferred therapeutic outcome, as occurs in the treatment of degenerative disorders [9, 28, 29] . As already shown for some ligand-gated ion channels, allosteric modulators have several advantages over orthosteric ligands as potential therapeutic agents. Such is the case for GAL, which has dual action at the cholinergic synapses both as CHE-I and as allosteric modulator on the alpha 7 nicotinic receptor [9, 28, 29] .
Although in the current study the information regarding the binding of (1) on M1 mAChR is only supported by computational docking simulations, this observation suggests that (1) could be an allosteric ligand on M1 mAChR. As can be seen in Fig. (5) , ligand (1) interacts with an allosteric binding on the M1 mAChR. This finding together with previous studies that show that (1) [11, 30] is a potent inhibitor on acetylcholinesterase, suggest that at least one of the two succinic acid derivatives could represent a novel candidate for the therapy of AD. However, further experimental evidence designed to confirm these results is required.
